This presentation is going to talk about the evolution of combination of target therapy and chemotherapy, standard regimens including anthracycline based, anthracycline-free and Taxane. For low risk patients or patients with comorbidities, how to balance between efficacy and side effect profile?

Last but not least, Dr. Tsai will talk about her insights on cancer treatment without chemotherapy. 

As a groundbreaking anti-cancer drug, T-DXd has demonstrated significant efficacy in clinical trials for patients with HER2-low metastatic breast cancer (mBC). This lecture aims to explore the optimal utilization of T-DXd in the treatment of HER2-low mBC and provide precise treatment recommendations based on patient-specific characteristics. 

Due to the high prevalence rate of breast cancer, treatment of breast cancer has been a big topic over decades. The treatment paradigm of breast cancer shifts with time and medicine development, from CMF to Anthracyclines, and Taxane. We foresee more and more different classes of drugs would evolve and help too. 

This presentation will review the current treatment of early breast cancer and share insights on the pros and cons of different regimens based on clinical evidence.

Anthracyclines have been a mainstay of breast cancer therapy for decades, with strong evidence demonstrating their impact on breast cancer survival. Apart from the proven efficacy, associated toxicity has raised concern on the use of anthracyclines and turned the spotlight on anthracycline-free regimens.
This presentation will review the role of anthracyclines in treatment of early breast cancer and share insights on anthracycline-free regimen based on clinical evidence.

時間:2023年11月15日(三)18:50-21:00 ，地點:乳e學院線上直播

2023乳癌新知研討會，今年度共3場會議，將於6/30, 7/28, 8/30，改採線上課程進行，歡迎有意報考乳房專科醫師的學員及各位會員踴躍上網觀看影片!